Antifungal Specialist F2G Gets Near $61m Financing
Now Hopes For Early FDA Approval Of Lead Asset
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.